Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT04172532

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Locally Advanced Pancreatic Adenocarcinoma Stage III Pancreatic Cancer AJCC v8

Interventions Biopsy Procedure Biospecimen Collection Computed Tomography Hypofractionated Radiation Therapy Magnetic Resonance Imaging Peposertib Placebo Administration

Updated 58 times since 2019 Last updated: Mar 12, 2026 Started: Jan 11, 2021 Primary completion: Aug 1, 2026 Completion: Aug 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Locally Advanced Pancreatic Adenocarcinoma and Stage III Pancreatic Cancer AJCC v8 and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 58 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

58 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 53 earlier versions

Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE1/PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2

Status: Suspended → Recruiting
Sep 2024 — Oct 2024 [monthly]

Suspended PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Suspended PHASE1/PHASE2

Status: Recruiting → Suspended
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Suspended → Recruiting
Apr 2024 — Jun 2024 [monthly]

Suspended PHASE1_PHASE2
Jan 2024 — Apr 2024 [monthly]

Suspended PHASE1_PHASE2
Nov 2023 — Jan 2024 [monthly]

Suspended PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Suspended → Recruiting
Nov 2022 — Jan 2023 [monthly]

Suspended PHASE1_PHASE2
Sep 2022 — Nov 2022 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
May 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE1_PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE1_PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE1_PHASE2
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE1_PHASE2
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE1_PHASE2
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1_PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jun 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jan 2020 — Jun 2020 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Dec 2019 — Jan 2020 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Buffalo, United States , Chicago, United States , Clemmons, United States , Detroit, United States , Duarte, United States , Fairway, United States , Farmington Hills, United States , Hays, United States , Irvine, United States and 27 more locations